ReviewActa paediatrica (Oslo, Norway : 1992)2026
The New Era of Respiratory Syncytial Virus Protection for Infants: A Mini Review of Current Tools for Immunoprophylaxis.
Review in Acta paediatrica (Oslo, Norway : 1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
aimThis mini review describes the history of infant respiratory syncytial virus (RSV) immunoprophylaxis and the latest advances in this area. It also reviews the efficacy, safety and impact of the recently introduced prophylactic strategies.
methodThis narrative review is based on a targeted review of published literature, with emphasis on pivotal clinical trials, regulatory documents and recent real-world evidence.
resultsThree immunisation products for preventing RSV in infants have been approved since 2022. These are two long-acting monoclonal antibodies, nirsevimab and clesrovimab, and a maternal RSV vaccine. The efficacy of these interventions has ranged from 49% to 76% against medically attended RSV-associated lower respiratory tract infections and from 55% to 91% against hospitalisation due to RSV-associated lower respiratory tract infection. The efficacy varied between the products and the duration of the follow-up. Similar or higher effectiveness has been reported in post-licensure, real-world evidence studies. Overall, these interventions have been well tolerated, with favourable safety profiles.
conclusionThe newly introduced long-acting monoclonal antibodies and the maternal RSV vaccine have proved highly effective and have demonstrated reassuring safety. They have already been implemented in a number of countries and have substantially reduced the RSV burden in infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.